NASDAQ:VRTX
Vertex Pharmaceuticals Inc. / Ma
Vertex Pharmaceuticals Inc. / Ma's revenue grew 8.9% in fiscal 2025 to $12.0B while operating margin rose to 34.8%. Free cash flow was $3.2B, 26.6% of revenue.Summary generated from Vertex Pharmaceuticals Inc. / Ma's SEC filings. Latest annual report filed Feb 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$12.0B
Revenue growth+8.9%
Revenue, 5-yr CAGR+14.1%
Gross margin86.2%
Operating margin34.8%
Net margin32.9%
ROICn/a
Return on equity22.5%
Debt / equityn/a
Free cash flow$3.2B
FCF margin26.6%
Share count change+0.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6 | 8.9 | 9.9 | 11.0 | 12.0 |
| Operating income | 2.8 | 4.3 | 3.8 | −0.2 | 4.2 |
| Net income | 2.3 | 3.3 | 3.6 | −0.5 | 4.0 |
| Free cash flow | 2.4 | 3.9 | 3.3 | −0.8 | 3.2 |
Recent filings
- 4Insider transaction report
Sep 10, 2026 - 4Insider transaction report
Sep 1, 2026 - 8-KDirector or officer change
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KEntry into a material agreement
Jul 7, 2026 - 8-KDirector or officer change
May 13, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026